News

Larka Supports Albumedix' Sale Process, Acquired by Sartorius

26 October 2022 - Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Albumedix – a leading recombinant albumin-based solution provider based in Nottingham, UK – acquired by the Sartorius Group.

Larka Advises Keensight on CRO Axxam Acquisition

1 September 2022 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence provider to support Keensight Capital on its acquisition of a majority stake in Axxam, a global-leading Contract Research Organization (CRO) based in Italy.

Larka Advises Cathay on its Investment in CRO Transcure

31 August 2022 - Larka is thrilled to announce it performed the Commercial Due Diligence to support Cathay Capital’s investment in TransCure bioServices, a global-leading Contract Research Organization (CRO) based in France.

Larka Advises Merieux Equity Partners on its investment in Janvier Labs

26 July 2022 - Larka provides Merieux Equity Partners with a Commercial Due Diligence to support its investment in French BioPharma company Janvier Labs.

Larka Advises Elyan on CRO Oncodesign Acquisition Process

11 July 2022 - Larka provides Elyan Partners with a Commercial Due Diligence to support the acquisition of CRO services Business Unit of Oncodesign, a leading French BioPharma company.

Larka Advises Gimv on CDMO BioConnection Investment Deal

24 May 2022 - Larka provides Gimv with a Technical Due Diligence and Operational Due Diligence to support its investment in leading Dutch bio-CDMO BioConnection.

Interview with: Yana Marmann

25 April 2022 - Fresh out of college and hired amid the COVID-19 pandemic, Yana saw in Larka an opportunity to shape a career within the BioPharma industry while evolving in a fast-paced and exciting environment.

Vendor Due Diligence for Afinum and SHS | evitria

27 July 2021 - Larka is very pleased to announce that it’s M&A Unit performed the Vendor Commercial Due-Diligence to support Afinum’s exit process of evitria, a global leading service provider specialized in transient antibody expression.

Commercial Due Diligence for Keensight Capital | Symeres

7 June 2021 - Larka is very proud to announce that it performed the Commercial-Due-Diligence for Keensight Capital on its acquisition of Symeres.

Commercial Due Diligence for Clean Biologics & Archimed | Biodextris

11 May 2021 - Larka is pleased to announce that it performed the Commercial Due-Diligence for Clean Biologics group – backed by Archimed - on their acquisition of Biodextris.

Olivier Dumortier PhD Appointed as Business Development Manager

12 April 2021 - Prior to joining Larka’s Analysts team two years ago, Olivier did a PhD thesis in Belgium - exploring numerous models of metabolic diseases - then worked on non-coding RNA and regulation of cell metabolism and physiology in Canada and France for over a decade.

Maxime Clarhaut Appointed as Associate

8 April 2021 - Maxime has been working with Larka’s Analyst team for over two years now and keeps proving that dedication, combined with passion for Biotech and Pharma industry, lead to great achievements and value creation for our clients.

Lucas Leray joins Larka as Digital Marketing Manager

11 February 2021 - Lucas will be a valuable asset for our Marketing & Sales Business Unit, as he brings strong expertise in both Research Marketing and Digital Marketing, particularly cruci

New Office

9 August 2020 - As a result of a strong and continued growth in recent years, we are delighted to announce the opening of our new office in Nice.

New Brand Identity

2 August 2020 - We are pleased to unveil our new logo and brand identity, reflecting the company’s values, culture and leadership position in the management consulting services and BPI.

New Website

27 July 2020 - After months of combined development efforts from our digital marketing and IT teams, we are delighted to announce the official launch of Larka's brand new website.

Integrated Due Diligence for Cathay Capital | Biose

20 July 2020 - Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Cathay Capital.

Integrated Due Diligence for Keensight Capital | 3P Biopharmaceuticals

30 July 2019 - Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Keensight Capital.

Integrated Due Diligence for Archimed | Clean Cells

3 December 2018 - Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Archimed.